Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us
Fuzuloparib

Sourced directly from the authorized manufacturer network to ensure authenticity and quality.

Ready to proceed? Order Fuzuloparib on our secure patient portal to submit your prescription, upload documents and track your approval status.

Fuzuloparib

Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.

Medicine Name: Fuzuloparib
Generic Name (API): Fuzuloparib
Dosage Form & Strength: 50 mg
Route: Oral
Drug Class: PARP (PARP1/PARP2) inhibitor

Manufacturer / Innovator:

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Regulatory Approval:

  • NMPA (China)
Family enjoying life with Named Patient Program access

Your Trustworthy Partner For Named Patient Program

  • your trusted partner for named patient program

    Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.

  • 100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

    100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

  • Medicines sourced from authorized manufacturers with full batch traceability

    Medicines sourced from authorized manufacturers with full batch traceability.

  • EU-GDP Compliant Warehousing for secure, quality-controlled global distribution.

    EU-GDP compliant warehousing for secure, quality-controlled global distribution.

  • Temperature-Controlled Logistics for Safe and Timely Delivery

    Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.

GDP Compliant View Certificate
Licensed Wholesale distributor View Certificate

What Is Fuzuloparib Used For?

Fuzuloparib is a capsule taken by mouth for women with ovarian cancer and, more recently, for some women with advanced breast cancer linked to an inherited BRCA gene change. It was developed in China by Jiangsu Hengrui Pharmaceuticals Co., Ltd. and is sold there as 艾瑞颐 (AiRuiYi®). Earlier papers spell it fluzoparib, and its development code was SHR3162.

China's National Medical Products Administration (NMPA) first approved it in December 2020 and has added uses since. As listed by the company in October 2025, the approved uses in China are:

  • Ovarian, fallopian tube or primary peritoneal cancer with a germline BRCA mutation that has come back while still platinum-sensitive, after two or more earlier lines of chemotherapy (December 2020)
  • Maintenance after relapse: adults with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whose disease has shrunk completely or partly on platinum chemotherapy (June 2021)
  • First-line maintenance: adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in complete or partial response after first platinum chemotherapy (May 2024)
  • HER2-negative metastatic breast cancer with a germline BRCA mutation in adults who have already had chemotherapy, alone or together with a second targeted tablet from the same maker; hormone receptor-positive disease must also have had hormone treatment or be unsuitable for it (December 2024)

A gynaecological or medical oncologist decides whether it fits a particular case, usually after BRCA testing. Our ovarian cancer medicines section lists other treatments we can help import.

How It Works

Cells repair everyday DNA damage with the help of PARP enzymes. Cancer cells that carry a faulty BRCA1 or BRCA2 gene already have a weak back-up repair system, so when this capsule blocks PARP1 and PARP2 the damage builds up and the cancer cells die, while normal cells cope better. This approach is called synthetic lethality, and it is why BRCA status matters so much when choosing it.

What the Trials Showed

  • Relapsed BRCA-mutated ovarian cancer (phase 2, 113 women): tumours shrank in 69.9% on independent review, and the median time without progression was 12.0 months.
  • FZOCUS-2, maintenance after relapse (252 women): median progression-free survival was 12.9 months versus 5.5 months on placebo, a 75% lower risk of progression (HR 0.25). The benefit was seen with and without a BRCA mutation.
  • FZOCUS-1, first-line maintenance (674 women randomised): used alone it gave a median progression-free survival of 29.9 months against 11.1 months on placebo (HR 0.58).
  • FABULOUS, BRCA-mutated breast cancer (203 women): median progression-free survival was 6.7 months alone and 11.0 months with the partner tablet, compared with 3.0 months on standard chemotherapy.

Recommended Dosage

  • Capsule strength: 50 mg
  • Dose used alone: in all the ovarian trials and the single-agent breast arm, 150 mg (three 50 mg capsules) twice a day, in continuous 28-day cycles
  • Dose in the breast combination: 100 mg twice a day together with the partner tablet, as set by the oncologist
  • Dose changes: if blood counts fall, doses are paused or lowered; in the phase 2 study 39.8% of women needed a pause and 34.5% a lower dose, while only 0.9% stopped because of side effects
  • How long: it continues while it keeps the cancer under control and side effects remain manageable

Exact instructions, including food timing, should be taken from the Chinese package insert supplied with the capsules and from the treating doctor.

This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.

Warnings and Precautions

Who should not take it: anyone allergic to the active substance or any ingredient of the capsule. The main safety issue is the bone marrow, so blood tests are part of every month of treatment.

  • Anaemia: the most frequent serious problem. Severe anaemia affected 25.1% of women in FZOCUS-2 and 23.8% in the single-agent arm of FZOCUS-1. Tiredness, breathlessness or paleness should be reported, as a transfusion or dose break may be needed.
  • Low platelets: severe in 16.8% (FZOCUS-2) and 12.6% (FZOCUS-1). Watch for easy bruising, nosebleeds or bleeding gums.
  • Low neutrophils and white cells: severe neutrophil drops in 12.6% and 11.5% respectively, which raises the risk of infection. A fever during treatment needs prompt medical attention.
  • Stomach effects: nausea, vomiting and tiredness were the most common non-blood side effects and were mostly mild; severe nausea was seen in just one patient in FZOCUS-2 (0.6%).
  • Other laboratory changes: in FZOCUS-1 a small number had high triglycerides (2.6% severe) or raised ALT liver enzyme (1.5% severe), so routine blood chemistry is checked too.

Monitoring: a full blood count is usually done before starting and regularly afterwards, more often in the first months. Most severe blood-count drops in the trials settled within one to two weeks after a pause or dose reduction. Other points: tell the oncologist about every other medicine and supplement, since interactions are possible. Pregnancy, contraception and breastfeeding should be discussed before starting, and the full warnings in the Chinese package insert should be followed.

How to Access Fuzuloparib in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Fuzuloparib to India?

Supply is arranged in the name of one patient, with the request coming from the family or the hospital, under India's rules for importing unapproved medicines. Please keep these ready:

  • A prescription from a gynaecological or medical oncologist stating the dose
  • The histopathology report and, for most uses, the germline BRCA test report
  • A note on earlier treatment, including how the cancer responded to platinum chemotherapy
  • A recent blood count and the patient's government-issued photo ID

How is the order confirmed?

Once we have checked a valid prescription and, where required, the import permit has been issued.

Is Fuzuloparib available in India?

No. CDSCO has not approved it, so chemists in India cannot keep it on their shelves. China is the only country where it is approved; the US FDA has not approved it, and a European application for prostate cancer was only accepted for review in October 2026.

A doctor can still request it under the Named Patient Program (NPP), which allows an unregistered medicine to be imported for a single patient on prescription. Families can also ask us about senaparib, another China-approved ovarian cancer capsule.

It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.

Sourcing & Delivery

NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The capsules stay in their sealed Chinese packs and are stored and shipped as directed on the pack, using temperature-controlled shipping so they are not exposed to heat on the way. At 150 mg twice a day a patient takes six capsules daily, so we plan each order around a full month and send the next supply before the current one runs out. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.

For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.

Availability Across Major Cities in India

Maintenance treatment with this capsule often lasts many months, so families need a supply they can rely on. After the paperwork is cleared, we deliver to these cities and to smaller towns across the country.

Delhi

Gynae-oncology units in Delhi can share the BRCA report and prescription, and the capsules leave from our New Delhi base.

Mumbai

For women finishing platinum chemotherapy in Mumbai, we can time the first supply to the start of maintenance.

Bangalore

Families in Bangalore receive a written quote for one month first, so the decision is made without pressure.

Chennai

Oncologists in Chennai can send recent blood counts with the order, which helps us confirm the right dose before dispatch.

Hyderabad

Breast cancer teams in Hyderabad treating BRCA carriers can request it once the HER2-negative status is on file.

Kolkata

For Kolkata and the north-eastern states, each month's parcel is tracked and the reference shared with the family.

Pune

In Pune, we help families keep a steady supply, because maintenance treatment runs for many months.

Ahmedabad

Doctors in Ahmedabad can check with us which documents are still missing before the import permit is filed.

Jaipur

For women in Jaipur and wider Rajasthan, parcels can go to home or to the cancer hospital pharmacy.

Lucknow

Families in Lucknow can choose delivery close to the clinic where monthly blood tests are done.

Bhubaneswar

Oncology centres in Bhubaneswar can ask for the capsules for a named patient after the BRCA test is reported.

Kochi

Across Kerala, monthly supplies reach Kochi, Thiruvananthapuram or a town near the patient.

Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.

Author Details

Nitin Goswami

Written By

Nitin Goswami

Deputy Manager – Content & Social Media, Ikris Pharma Network

Sources: NMPA • CDSCO

Dr. Chirag C Shah

Medically Reviewed By

Dr. Chirag C Shah

MBBS

Last Updated: 20 November 2026

More Oncology Medicines

TRUSTED BY HEALTHCARE PROFESSIONALS & HOSPITALS

Need Help
Accessing Medicines?

Our specialists are here to guide you through every step of the medicine access process.

Let's us help!

Send us a message

Read how to access medicines

Read More arrow icon

Frequently Asked
Questions

Read More
Meet the NPP Assistant: ask us anything about NPP